Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 5/20 | 0.44 |
| ▸ | TMEM97 | Q5BJF2 | 2/20 | 0.44 |
| ▸ | CCR5 | P51681 | 4/20 | 0.40 |
| ▸ | HTR2A | P28223 | 6/20 | 0.38 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.38 |
| ▸ | DRD2 | P14416 | 1/20 | 0.36 |
| ▸ | DRD3 | P35462 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Cadaverine Tartrate SCHEMBL5927236 | 0.95 | OPRM1 (0.42) | OPRM1TMEM97CCR5HTR2A | |
| SCHEMBL341923 | 0.89 | OPRM1 (0.51) | OPRM1TMEM97CCR5HTR2A | |
| SCHEMBL341231 | 0.87 | OPRM1 (0.47) | OPRM1TMEM97CCR5HTR2ADRD2 | |
| SCHEMBL340611 | 0.85 | OPRM1 (0.47) | OPRM1TMEM97CCR5HTR2A | |
| Cadaverine Tartrate SCHEMBL10321941 | 0.84 | OPRM1 (0.48) | OPRM1TMEM97CCR5HTR2A | |
| SCHEMBL340153 | 0.83 | NSD2 (0.48) | OPRM1TMEM97CCR5HTR2A | |
| Cadaverine Tartrate SCHEMBL10322305 | 0.83 | OPRM1 (0.44) | OPRM1TMEM97CCR5HTR2A | |
| SCHEMBL342709 | 0.82 | CCR5 (0.50) | OPRM1TMEM97CCR5HTR2A | |
| SCHEMBL340784 | 0.81 | HTR2A (0.55) | OPRM1TMEM97HTR2A | |
| SCHEMBL341169 | 0.80 | HTR2A (0.60) | OPRM1HTR2ACHRM1DRD3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7538222-B2 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | claimed |
| US-20060205722-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2006-09-14 | — | — | US | claimed |
| US-20060199818-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS INC. | 2006-09-07 | — | — | US | claimed |
| US-20060094758-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | claimed |
| EP-1562937-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | Acadia Pharmaceuticals Inc. (US) | 2005-08-17 | — | — | EP | claimed |
| US-20040106600-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | claimed |
| WO-2004000808-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-31 | — | — | WO | claimed |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | Sunovion Inc. (US) | 2012-05-17 | — | — | US | disclosed |
| US-8097625-B2 | Combination of sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | SUNOVION PHARMACEUTICALS INC. (US) | 2012-01-17 | — | — | US | disclosed |
| EP-2343073-A2 | Combination of a sedative and a neurotransmitter modulator, and methods for improving sleep quality and treating depression | Sepracor Inc. (US) | 2011-07-13 | — | — | EP | disclosed |
| US-7538222-B2 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. (US) | 2009-05-26 | — | — | US | disclosed |
| US-7476682-B2 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. (US) | 2009-01-13 | — | — | US | disclosed |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | ACADIA PHARMACEUTICALS INC. | 2008-02-28 | — | — | US | disclosed |
| EP-1691811-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | Sepracor, Inc. (US) | 2006-08-23 | — | — | EP | disclosed |
| US-20060094758-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2006-05-04 | — | — | US | disclosed |
| EP-1562937-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | Acadia Pharmaceuticals Inc. (US) | 2005-08-17 | — | — | EP | disclosed |
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | SEPRACOR, INC. (US) | 2005-08-11 | — | — | US | disclosed |
| WO-2005060968-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR IMPROVING SLEEP QUALITY AND TREATING DEPRESSION | SEPRACOR INC. (US) | 2005-07-07 | — | — | WO | disclosed |
| US-20040106600-A1 | N-substituted piperidine derivatives as serotonin receptor agents | ACADIA PHARMACEUTICALS, INC. | 2004-06-03 | — | — | US | disclosed |
| WO-2004000808-A2 | N-SUBSTITUTED PIPERIDINE DERIVATIVES AS SEROTONIN RECEPTOR AGENTS | ACADIA PHARMACEUTICALS INC. (US) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050176680-A1 | Eszopiclone stimulates GABA receptors, and serotonin reuptake inhibitor (citalopram), norepinephrine reuptake inhibitor (desipramine), 5-HT2A modulator, or dopamine reuptake inhibitor (amineptine) | HTR2A, HTR2C, HTR5A | OPRM1 77/4885TMEM97 232/4885CCR5 570/4885 |
| US-20040106600-A1 | N-substituted piperidine derivatives as serotonin receptor agents | HTR1A, HTR5A, HTR1B | OPRM1 40/4885TMEM97 142/4885CCR5 1728/4885 |
| US-20060094758-A1 | N-substituted piperidine derivatives as serotonin receptor agents | HTR1A, HTR5A, HTR1B | OPRM1 40/4885TMEM97 130/4885CCR5 1560/4885 |
| US-20080051429-A1 | USE OF 4-AMINO-PIPERIDINES FOR TREATING SLEEP DISORDERS | HTR4, HTR3B, HTR2A | OPRM1 98/4885TMEM97 510/4885CCR5 1541/4885 |
| US-20120122874-A1 | COMBINATION OF A SEDATIVE AND A NEUROTRANSMITTER MODULATOR, AND METHODS FOR TREATING DEPRESSION | HTR2A, HTR5A, HTR2C | OPRM1 93/4885TMEM97 171/4885CCR5 553/4885 |
| US-20060205722-A1 | N-substituted piperidine derivatives as serotonin receptor agents | HTR1A, HTR5A, HTR1B | OPRM1 40/4885TMEM97 130/4885CCR5 1560/4885 |
| US-20060199818-A1 | N-substituted piperidine derivatives as serotonin receptor agents | HTR1A, HTR5A, HTR1B | OPRM1 40/4885TMEM97 130/4885CCR5 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.